Description du projet
Améliorer la sécurité des médicaments
Des faits dommageables associés à certains médicaments pharmaceutiques sont connus sous le terme d’effets indésirables d’un médicament (EIM) et pourraient être liés à la dose ou à la période d’administration. Ils pourraient également résulter de l’arrêt ou de l’échec du traitement. Le projet MEDIKURA, financé par l’UE, a développé une infrastructure numérique pour collecter et analyser les données relatives aux EIM dans le but d’améliorer la sécurité des médicaments. La plateforme basée sur le cloud est accessible aux patients, médecins et entreprises pharmaceutiques en tant qu’approche transparente et centralisée de l’établissement de rapports sur les EIM. À long terme, cette plateforme devrait accélérer la découverte de médicaments fondée sur les données et minimiser les EIM.
Objectif
The mission of MEDIKURA is to digitize drug safety: our process innovation helps pharma companies to capture, enrich, and analyze drug-related data provided by patients and doctors. We address the societal problem that more than 200,000 European citizens die from Adverse Drug Reactions (ADRs, colloquially referred to as drug side-effects) every year, whereas less than 1% of ADR cases are officially reported by patients and doctors. To improve drug safety, the new EU regulation ICH E2B(R3) came into effect in late 2017 - as a result, pharma companies are subject to increasing cost and time pressure in ADR monitoring.
Our solution is to build the digital infrastructure for ADR data – to improve drug safety, enable more targeted therapies, and accelerate data-driven drug discovery. We streamline the process of capturing, enriching, and analyzing ADR data through a cloud-based platform that connects pharma companies with patients and doctors. Our goal is to replace the decentralized, analogue drug safety process with a transparent, centralized, and digital system. The resulting value proposition to pharma companies is three-fold. In terms of time savings, we reduce the timespan to close a ADR case and report it to public authorities by more than 50%. In terms of money, we can save processing cost of more than 50% per ADR case and reduce liability risk significantly. In terms of data quality, we provide comprehensive information through a digital backchannel to both patients and doctors that allows to enrich drug-related data and prepare it for subsequent analyses.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencescomputer and information sciencesdata sciencedata exchange
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
80335 MUNCHEN
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.